Expression of Vascular endothelial growth factor (VEGF) and CD34 in different thyroid disorders

Liana Gogiashvili, Tamuna Gvianishvili, Elene Nikobadze, Tinatin Kvachadze, Ekaterine Melikadze, Ketevan Jandieri


Background: Neovascularization/angiogenesis is crucial for the growth and metastatic spread of neoplasms. It is a key reaction to evaluate the growth potential of neoplasms, a multi-step process related to the modeling of the intercellular matrix, proliferation and migration of endothelial cells.

Aim: Study of the vascular density during Hashimoto’s Thyroiditis (HT) and Papillary Thyroid Carcinoma (PTC) by immunohistochemical examination of angiogenesis activity: VEGF, CD34 markers.

Methods: The research database is retrospective and prospective tissue samples obtained from patients after total thyroidectomy, lobectomy or partial resection: HT (n=25), PTC (n =10) which studied histologically and immunohistochemically investigated.

Results: VEGF expression reduced as compare cases of HT than in PTC. There was no clear association between CD34 and thyroid pathology.

Conclusion: VEGF is the most potent inducer of neovascularization, and its increased expression is associated with a poor prognostic outcome in many diseases. It is known that TTF-1 positively regulates VEGF. But it should be noted that, in terms of manifestation time, the action of VEGF is primarily than TTF1, and may be discussed as a predictor of dysplasia and malignant transformation.


Hashimoto’s Thyroiditis; Papillary Thyroid Carcinoma; VEGF; CD34; TTF-1

Full Text:



Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences. 2020; 77(9): 1745–1770. doi: 10.1007/s00018-019-03351-7

Fares Hezam Al-Ostoot, Salma Salah, Hussien Ahmed Khamees, Shaukath Ara Khanum. Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treatment and Research Communications. 2021; 28.

SrujanaJoga, Venkata Pradeep Babu Koyyala. Angiogenesis in Cancer. Indian Journal of Medical and Paediatric Oncology 2021;42:168–171

Carmen StancaMelincovici, Adina Bianca Boşca, Sergiu Şuşman, Mariana Mărginean, Carina Mihu, MihneaIstrate, Ioana Maria Moldovan, Alexandra Livia Roman, Carmen Mihaela Mihu. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian Journal of Morphology and Embryology. 2018;59(2):455-467.

Masabumi Shibuya. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis. Genes & Cancer. 2011; 2(12): 1097–1105. doi:10.1177/1947601911423031

Masabumi Shibuya. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. The Journal of Biochemistry. 2013; 153(1): 13–

Nader Rahimi. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Frontiers in Bioscience. 2006; 11: 818–829. doi: 10.2741/1839

Yoon-Jin Lee, Daniel L Karl, Ugwuji N Maduekwe, Courtney Rothrock, Sandra Ryeom, Patricia A D'Amore, Sam S Yoon. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Research. 2010;70(21):8357-67. doi: 10.1158/0008-5472.CAN-10-1138.


Bariya Deepak; Mishra, Shashi Prakash; Akshay, BR; Kumari, Sweety; Akanksha, Khanna, Rahul; Meena, Ram Niwas. Relationship between vascular endothelial growth factor expression and thyroid stimulating hormone level in benign and malignant thyroid lesions. Journal of Family Medicine and Primary Care. 2022; 11(6): 2565-2572. DOI: 10.4103/jfmpc.jfmpc_1126_21

Chen-ran Guo, Rui Han, Feng Xue, Lin Xu, Wan-gang Ren, Meng Li, Zhen Feng, Ben-chuang Hu, Zhong-min Peng. Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT. Frontiers in Oncology. 2022; 12: 956451. doi: 10.3389/fonc.2022.956451

Sebastian Hoffmann, Lorenz C Hofbauer, Vera Scharrenbach, Anette Wunderlich, Iyad Hassan, Susanne Lingelbach, Andreas Zielke. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. The Journal of Clinical Endocrinology & Metabolism. 2004;89(12):6139-45. doi: 10.1210/jc.2004-1260.

M Klein, B Catargi. VEGF in physiological process and thyroid disease. Annales d'Endocrinologie. 2007;68(6):438-48. doi: 10.1016/j.ando.2007.09.004.

Mehdi Hassanpour, Amankeldi A. Salybekov, Shuzo Kobayashi, Takayuki Asahara. CD34 positive cells as endothelial progenitor cells in biology and medicine. Frontiers in Cell and Developmental Biology. 2023;

Nur Hidayati Mohamad PakarulRazy, Wan Faiziah Wan Abdul Rahman, Thin Thin Win. Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study. Asian Pacific Journal of Cancer Prevention. 2019;20(1):277-282. doi: 10.31557/APJCP.2019.20.1.277.

P. Malkomes, E. Oppermann, W. O. Bechstein, K. Holzer. Vascular Endothelial Growth Factor – Marker for Proliferation in Thyroid Diseases? Experimental and Clinical Endocrinology & Diabetes. 2013; 121: 6–13.

Varsha Dalal, Manveen Kaur, Anju Bansal. Papillary carcinoma thyroid with anastomosing channels: An unusual morphology. Journal of Laboratory Physicians. 2017; 9(2): 140–142. doi: 10.4103/0974-2727.199631

Ala'eddinJebreel, James England, Karen Bedford, Justin Murphy, Laszlo Karsai, Stephen Atkin.Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseasesInternational Journal of Experimental Pathology. 2007; 88(4): 271–277.doi: 10.1111/j.1365-2613.2007.00533.x

L AAkslen, V A Livolsi. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Human Pathology. 2000;31(4):439-42. doi: 10.1053/1-ip.2000.6548.

Lauren W. Wood, Nicole I. Cox, Cody A. Phelps, Shao-Chiang Lai, Arjun Poddar, Conover Talbot Jr., David Mu. Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. Scientific Reports volume 6, Article number: 19857 (2016) DOI: 10.1038/srep19857

GvianishviliT.Hashimoto Thyroiditis as Possible Predicting of Fillicular Epithelial Dysplasia. SEEMF Tenth Anniversary International Medical Congress Clinical & Translational Medicine Challenges in the Healthcare Systems - 21st Century. Values & Principles. 2019.

Gvianishvili T., Gogiashvili L.,Chkhobadze M. Molecular-biological thyroid profile during autoimmune disease - Hashimoto and Riedel’s Thyroiditis. Georgian Medical News №5 (290), 2019, ISSN 1512-0112


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)